Skip to main content

Advertisement

SpringerLink
Log in

Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Analyzed datasets are available from the corresponding author on reasonable request.

References

  1. Elia G, Patrizio A, Ragusa F, et al. Molecular features of aggressive thyroid cancer. Front Oncol. 2022;12:1099280. https://doi.org/10.3389/fonc.2022.1099280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest. 2021;131. https://doi.org/10.1172/JCI144847.

  3. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21:1028–35. https://doi.org/10.1158/1078-0432.CCR-14-2915.

    Article  CAS  PubMed  Google Scholar 

  4. Groussin L, Bessiene L, Arrondeau J, Garinet S, Cochand-Priollet B, Lupo A, et al. Letter to the Editor: Selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid. 2021;31:1603–4. https://doi.org/10.1089/thy.2021.0144.

    Article  PubMed  Google Scholar 

  5. Werner RA, Sahyeli C, Hänscheid H, et al. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:1833–18346.

    Article  CAS  PubMed  Google Scholar 

  6. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825–35. https://doi.org/10.1056/NEJMoa2005653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Departement of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland

    Daniela Weiler MD

  2. Departement of Nuclear Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland

    Maria del Sol Pérez Lago MD

Authors
  1. Daniela Weiler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria del Sol Pérez Lago MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors contributed to the publication. The case desription was performed by Daniela Weiler, images and comments were prepared by Maria del Sol Pérez Lago. The first draft of the manuscript was written by Daniela Weiler and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Daniela Weiler MD.

Ethics declarations

Ethics approval

Libretto-001 trial has ethics approval.

Consent to participate and publish

Written informed consent was obtained from the patient.

Competing interests

Daniela Weiler has received speaker and consultant honoraria from Eli Lilly. Maria del Sol Pérez Lago declares no financial interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiler, D., Pérez Lago, M. Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2024). https://doi.org/10.1007/s00259-024-06747-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00259-024-06747-1

Search

Navigation